Vanda Pharmaceuticals Inc. (VNDA) Stock Price

VNDAStock

$4.03−23.53%52W

Market Cap$243.66M

P/E—

PEG Ratio2.23

Div yield—

Beta0.70

VNDA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-54.85%

Price vs S&P 500 (4W)-20.50%

PEG Ratio2.23

VGM Score44.36

Book Value / Share (Quarterly)$3.64

P/TBV (Annual)2.48x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-5.29%

Cash Flow / Share (Quarterly)$-2.53

Price vs S&P 500 (YTD)-66.23%

Gross Margin (TTM)93.74%

Net Profit Margin (TTM)-127.41%

EPS (TTM)$-4.63

10-Day Avg Trading Volume0.93M

EPS Excl Extra (TTM)$-4.63

Revenue Growth (5Y)-2.73%

EPS (Annual)$-3.74

ROI (Annual)-65.88%

Gross Margin (Annual)93.96%

Net Profit Margin (5Y Avg)-19.08%

Cash / Share (Quarterly)$2.81

Revenue Growth QoQ (YoY)-3.92%

ROA (Last FY)-45.09%

Revenue Growth TTM (YoY)6.02%

EBITD / Share (TTM)$-3.00

ROE (5Y Avg)-12.53%

Operating Margin (TTM)-86.07%

Cash Flow / Share (Annual)$-1.87

P/B Ratio1.11x

P/B Ratio (Quarterly)1.67x

Net Income / Employee (Annual)$-413,600

EV / Revenue (TTM)0.90x

ROA (TTM)-56.79%

EV / EBITDA (TTM)152.31x

EPS Incl Extra (Annual)$-3.74

Current Ratio (Annual)2.39x

Quick Ratio (Quarterly)1.40x

3-Month Avg Trading Volume0.96M

52-Week Price Return-23.53%

EV / Free Cash Flow (Annual)-31.46x

Revenue / Employee (TTM)$404,700

Tangible BV / Share (Quarterly)$1.77

P/S Ratio (Annual)1.13x

Asset Turnover (Annual)0.44x

52-Week High$9.94

Operating Margin (5Y Avg)-15.89%

EPS Excl Extra (Annual)$-3.74

CapEx CAGR (5Y)-11.13%

Tangible BV CAGR (5Y)-13.41%

26-Week Price Return-44.95%

Quick Ratio (Annual)2.19x

13-Week Price Return-25.92%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)1.61x

Enterprise Value$194.96M

Revenue / Share Growth (5Y)-4.00%

Asset Turnover (TTM)0.45x

Book Value / Share Growth (5Y)-7.68%

Revenue / Employee (Annual)$405,500

Inventory Turnover (Annual)7.29x

Pretax Margin (Annual)-64.16%

Cash / Share (Annual)$4.46

3-Month Return Std Dev37.22%

Gross Margin (5Y Avg)92.30%

Net Income / Employee (TTM)$-515,700

ROE (Last FY)-67.38%

EPS Basic Excl Extra (Annual)$-3.74

P/FCF (TTM)32.22x

Receivables Turnover (TTM)4.12x

EV / Free Cash Flow (TTM)-20.52x

Total Debt / Equity (Quarterly)0.03x

EPS Incl Extra (TTM)$-4.63

Receivables Turnover (Annual)4.25x

ROI (TTM)-83.20%

P/S Ratio (TTM)1.13x

Pretax Margin (5Y Avg)-10.44%

Revenue / Share (Annual)$3.67

Tangible BV / Share (Annual)$3.55

Price vs S&P 500 (52W)-39.06%

Year-to-Date Return-54.31%

5-Day Price Return-11.23%

EPS Normalized (Annual)$-3.74

ROA (5Y Avg)-8.20%

Net Profit Margin (Annual)-102.02%

Month-to-Date Return-17.92%

Cash Flow / Share (TTM)$0.25

EBITD / Share (Annual)$-2.45

Operating Margin (Annual)-69.95%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-12.23%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-4.63

P/TBV (Quarterly)3.44x

P/B Ratio (Annual)1.59x

Inventory Turnover (TTM)7.02x

Pretax Margin (TTM)-82.14%

Book Value / Share (Annual)$5.54

Price vs S&P 500 (13W)-28.60%

Beta0.70x

P/FCF (Annual)19.62x

Revenue / Share (TTM)$3.58

ROE (TTM)-84.95%

52-Week Low$4.00

vGradeC

gGradeD

mGradeC

vgmGradeC

VNDA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.59	-$1.04	-77.02%(-$0.45)
Q1 2026	May 6, 2026	-$0.69	-$0.82	-19.27%(-$0.13)
Q4 2025	Feb 11, 2026	-$1.32	-$2.39	-80.38%(-$1.07)
Q3 2025	Oct 29, 2025	-$0.45	-$0.38	+16.18%(+$0.07)
Q2 2025	Jul 31, 2025	-$0.36	-$0.46	-28.97%(-$0.10)

VNDA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VNDAVanda Pharmaceuticals Inc.	C	D	C	1.1x	6.0%	93.7%	—	$4.03
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals is a biopharmaceutical company developing therapies for neurology and psychiatry conditions with significant unmet medical needs. Its commercial portfolio includes HETLIOZ (for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome), Fanapt (schizophrenia), and PONVORY, with Fanapt generating the majority of revenue. The company operates primarily in the United States, with additional markets in Europe, Israel, and Canada, and maintains a pipeline of development-stage candidates.